article

1. Clinical Characteristics of Inpatients with Schizophrenia Spectrum Disorder Treated with Electroconvulsive Therapy: A Population-Level Cross-Sectional Study: Titre: Caractéristiques cliniques des patients hospitalisés présentant un trouble du spectre de la schizophrénie et traités par électrochocs : Une étude de population transversale..  Canadian journal of psychiatry. Revue canadienne de psychiatrie.  -. 2024
2. A systematic review in effects of glucagon-like peptide-1 (GLP-1) mono-agonists on functional connectivity: Target engagement and rationale for the development in mental disorders..  Journal of affective disorders.  321-327. 2024
3. Efficacy of esketamine for perinatal depression: a systematic review and meta-analysis..  CNS spectrums.  1-9. 2024
4. National Trends in and Concentration of Industry Payments to U.S. Psychiatrists, 2015-2021..  Psychiatric services (Washington, D.C.).  -. 2024
5. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®)..  Journal of affective disorders.  922-927. 2024
6. Correction: Subjective and objective measures of cognitive function are correlated in persons with Post-COVID-19 Condition: a secondary analysis of a Randomized Controlled Trial..  European archives of psychiatry and clinical neuroscience.  2024
7. Association between rumination, suicidal ideation and suicide attempts in persons with depressive and other mood disorders and healthy controls: A systematic review and meta-analysis..  Journal of affective disorders.  513-527. 2024
8. Electroencephalography (EEG) spectral signatures of selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs) and vortioxetine in major depressive disorder: A systematic review..  Journal of affective disorders.  798-819. 2024
9. Mental Health and Social Correlates of Reincarceration of Youths as Adults..  The journal of the American Academy of Psychiatry and the Law.  52:294-303. 2024
10. Subjective and objective measures of cognitive function are correlated in persons with Post-COVID-19 Condition: a secondary analysis of a Randomized Controlled Trial..  European archives of psychiatry and clinical neuroscience.  2024
11. Association between cognitive functioning, suicidal ideation and suicide attempts in major depressive disorder, bipolar disorder, schizophrenia and related disorders: A systematic review and meta-analysis..  Journal of affective disorders.  381-399. 2024
12. A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists..  Journal of affective disorders.  589-594. 2024
13. Preclinical and clinical efficacy of kappa opioid receptor antagonists for depression: A systematic review..  Journal of affective disorders.  816-827. 2024
14. post-hoc.  Current medical research and opinion.  40:1-1411. 2024
15. Impact of vortioxetine on depressive symptoms moderated by symptoms of anxiety in persons with post-COVID-19 condition: A secondary analysis..  Psychiatry research.  -. 2024
16. Comparing suicide completion rates in bipolar I versus bipolar II disorder: A systematic review and meta-analysis..  Journal of affective disorders.  480-488. 2024
17. Association between fatigue and depressive symptoms in persons with post-COVID-19 condition: a post hoc analysis..  Current medical research and opinion.  40:1203-1209. 2024
18. National Trends in Emergency Department Visits for Suicide Attempts and Intentional Self-Harm..  The American journal of psychiatry.  181:-. 2024
19. Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS)..  Expert opinion on drug safety.  1-5. 2024
20. How to Value a Life Without Limits: Quantifying Suffering With Quality-Adjusted Life-Years in Social Anxiety Disorder..  The Journal of clinical psychiatry.  85. 2024
21. The role of KCNQ channel activators in management of major depressive disorder..  Journal of affective disorders.  364-372. 2024
22. Risk of VMAT2 inhibitors on suicidality and parkinsonism: report utilizing the United States Food and Drug Administration adverse event reporting system..  International clinical psychopharmacology.  2024
23. National trends and correlates of treatment resistance in major depressive episode and associated suicidal ideation and behaviors among adults in the United States..  Journal of affective disorders.  342-349. 2024
24. Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: A systematic review and meta-analysis..  Journal of affective disorders.  684-698. 2024
25. Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis..  Journal of affective disorders.  753-762. 2024
26. Impact of elevated body mass index (BMI) on cognitive functioning and inflammation in persons with post-COVID-19 condition: a secondary analysis..  Acta neuropsychiatrica.  36:1-217. 2024
27. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review..  Journal of affective disorders.  342-354. 2024
28. Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review..  Expert opinion on pharmacotherapy.  25:467-476. 2024
29. Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine..  Advances in therapy.  41:1983-1994. 2024
30. Impacts of metabolic disruption, body mass index and inflammation on cognitive function in post-COVID-19 condition: a randomized controlled trial on vortioxetine..  Annals of general psychiatry.  23:-. 2024
31. The Top 50 Articles and Authors of the New Millennium in Psychiatry: A Bibliometric Analysis..  Cureus.  16:-. 2024
32. Recent Advances in the Treatment of Treatment-Resistant Depression: A Narrative Review of Literature Published from 2018 to 2023..  Current psychiatry reports.  26:176-213. 2024
33. Comparison of industry payments to psychiatrists and psychiatric advanced practice clinicians in the USA, 2021: a cross-sectional study..  BMJ open.  14:-. 2024
34. The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis..  Expert opinion on pharmacotherapy.  25:5-14. 2024
35. Neuropsychological Assessments of Cognitive Impairment in Major Depressive Disorder: A Systematic Review and Meta-Analysis with Meta-Regression..  Psychotherapy and psychosomatics.  93:8-23. 2024
36. Autoimmune and auto-inflammatory adverse events after COVID-19 vaccination in the United States..  Clinical immunology (Orlando, Fla.).  -. 2023
37. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data..  Journal of affective disorders.  314-322. 2023
38. Efficacy and safety of ketamine-assisted electroconvulsive therapy in major depressive episode: a systematic review and network meta-analysis..  Molecular psychiatry.  29:750-759. 2023
39. Impact of Elevated Body Mass Index (BMI) on Hedonic Tone in Persons with Post-COVID-19 Condition: A Secondary Analysis..  Advances in therapy.  41:686-695. 2023
40. Association of SARS-CoV-2 infection with neurological impairments in pediatric population: A systematic review..  Journal of psychiatric research.  90-110. 2023
41. Characterization of quality of life among individuals with current treated, untreated, and past alcohol use disorder..  The American journal of drug and alcohol abuse.  49:1-12. 2023
42. Estimates of loneliness among racially and ethnically diverse adults with serious mental illness in New York City boroughs: Manhattan, Bronx, and Brooklyn..  Journal of the American Geriatrics Society.  72:924-927. 2023
43. A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia..  Expert review of clinical pharmacology.  16:1085-1092. 2023
44. Gender Differences in Risks of Suicide and Suicidal Behaviors in the USA: A Narrative Review..  Current psychiatry reports.  25:809-824. 2023
45. Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders..  Drug discovery today.  28:-. 2023
46. Monotonic Association of Increasing Past-Year Substance Use Disorder across a Four-Level Trauma Post-Traumatic Stress Disorder (PTSD) Hierarchy in a Nationwide Sample..  Journal of dual diagnosis.  19:231-239. 2023
47. Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol..  Psychiatry research.  -. 2023
48. Is psychiatric diagnostic remission associated with reduced prevalence of moderate to severe pain interference and improved functioning among adults with lifetime psychiatric disorders?.  Journal of affective disorders.  585-591. 2023
49. Corrigendum to "COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis" [Brain Behav. Immun. 111 (2023) 211-229]..  Brain, behavior, and immunity.  -. 2023
50. Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials..  CNS drugs.  37:867-881. 2023
51. Exploring the potential of a bridge therapy: Synergistic approach integrating intravenous ketamine and intranasal esketamine for treatment-resistant depression..  Acta psychiatrica Scandinavica.  148:385-387. 2023
52. Emergency Department Use Among Recently Homeless Adults in a Nationally Representative Sample..  The western journal of emergency medicine.  24:894-905. 2023
53. Pain Management in Older Adults Before and During the First Year of COVID-19 Pandemic: Prevalence, Trends, and Correlates..  The journals of gerontology. Series A, Biological sciences and medical sciences.  78:1627-1640. 2023
54. Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder..  Journal of affective disorders.  893-898. 2023
55. Efficacy and Safety of Ketamine-assisted Electroconvulsive Therapy in Major Depressive Episode: A Systematic Review and Network Meta-Analysis..  Research square.  2023
56. Exploring Disparities in Behavioral Health Service Use in the Early Stages of the COVID-19 Pandemic..  International journal of behavioral medicine.  31:549-562. 2023
57. Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review..  Journal of psychiatric research.  80-89. 2023
58. National Trends in Mental Health-Related Emergency Department Visits Among Youth, 2011-2020..  JAMA.  329:1469-1477. 2023
59. Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials..  Expert opinion on investigational drugs.  32:1-15. 2023
60. Lived Experience-Led Research Agenda to Address Early Death in People With a Diagnosis of a Serious Mental Illness: A Consensus Statement..  JAMA network open.  6:-. 2023
61. Predicting the Behavioral Health Needs of Asian Americans in Public Mental Health Treatment: A Classification Tree Approach..  Administration and policy in mental health.  50:1-14. 2023
62. COVID-19 Vaccination for the Prevention and Treatment of Long COVID: A Systematic Review and Meta-analysis..  Brain, behavior, and immunity.  211-229. 2023
63. Increasing Use of Cannabis for Medical Purposes Among U.S. Residents, 2013-2020..  American journal of preventive medicine.  65:528-533. 2023
64. Association of SARS-CoV-2 Infection with Neurological Symptoms and Neuroimaging Manifestations in the Pediatric Population: A Systematic Review..  Research square.  2023
65. Association of Recent and Past Suicide Attempts With Health-Related Quality of Life..  The Journal of clinical psychiatry.  84. 2023
66. Mental health problems of black and white children in a nationally representative epidemiologic survey..  Psychiatry research.  -. 2023
67. Effects of Electroconvulsive Therapy on Functional Outcomes Among Medicare Patients With Comorbid Depression and Dementia: A Nationwide 1-Year Follow-Up Study..  The Journal of clinical psychiatry.  84. 2023
68. Homelessness and Treatment Outcomes Among Black Adults With Opioid Use Disorder: A Secondary Analysis of X:BOT..  Journal of addiction medicine.  17:463-467. 2023
69. Evaluating Anhedonia as a risk factor in suicidality: A meta-analysis..  Journal of psychiatric research.  209-215. 2022
70. Biomarkers of ketamine's antidepressant effect: An umbrella review..  Journal of affective disorders.  598-606. 2022
71. Durkheim's Theory of Social Integration and Suicide Revisited: Is It Diversity of Social Networks or Perceived Strength of Social Support That Matters?.  The Journal of clinical psychiatry.  84. 2022
72. Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis..  JAMA psychiatry.  79:1162-1172. 2022
73. The bidirectional association of nonalcoholic fatty liver disease with depression, bipolar disorder, and schizophrenia..  CNS spectrums.  28:1-20. 2022
74. Association of current and remitted bipolar disorders with health-related quality of life: Findings from a nationally representative sample in the US..  Journal of affective disorders.  33-40. 2022
75. Ketamine use in pediatric depression: A systematic review..  Psychiatry research.  -. 2022
76. National trends of suicidal ideation and mental health services use among US adults with opioid use disorder, 2009-2020..  EClinicalMedicine.  -. 2022
77. Racial and ethnic differences in suicidal behavior and mental health service use among US adults, 2009-2020..  Psychological medicine.  53:1-11. 2022
78. Rates and correlates of dual diagnosis among adults with psychiatric and substance use disorders in a nationally representative U.S sample..  Psychiatry research.  -. 2022
79. Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting..  JAMA psychiatry.  79:736-738. 2022
80. Women's Use of Substance Use Disorder Treatment Services: Rates, Correlates, and Comparisons to Men..  The Psychiatric quarterly.  93:737-752. 2022
81. Why are women more likely to attempt suicide than men? Analysis of lifetime suicide attempts among US adults in a nationally representative sample..  Journal of affective disorders.  157-164. 2022
82. Is legalization of recreational cannabis associated with levels of use and cannabis use disorder among youth in the United States? A rapid systematic review..  European child & adolescent psychiatry.  33:701-723. 2022
83.  
84. Transgenerational Factors Associated With Military Service: Comparison of Children of Veterans and Nonveterans in a Nationally Representative Sample..  Journal of the American Academy of Child and Adolescent Psychiatry.  61:1141-1154. 2022
85.  
86.  
87.  
88.  
89.  
90.  
91.  
92.  
93.  
94.  
95.  
96.  
97.  
98.  
99.  
100.  
101.  
102.  
103.  
104.  
105.  
106.  
107.  
108.  
109.  
110.  
111.  
112.  
113.  
114.  
115.  
116.  
117.  
118.  
119.  
120.  
121.  
122.  
123.  
124.  
125.  
126.  
127.  
128.  
129.  
130.  
131.  
132.  
133.  
134.  
135.  
136.  
137.  
138.  
139.  
140.  
141.  
142.  
143.  
144.  
145.  
146.  
147.  
148.  
149.  
150.  
151.  
152.  
153.  
154.  
155.  
156.  
157.  
158.  
159.  
160.